Global Tumor Necrosis Factor Inhibitor Drugs Market - 2022-2029

Global Tumor Necrosis Factor Inhibitor Drugs Market - 2022-2029

Market Overview

Tumor Necrosis Factor Inhibitor Drugs Market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 16.3% during the forecast period (2022-2029).

TNF inhibitors, also called TNF blockers, biologic therapies, or anti-TNF drugs, help stop inflammation. They treat Rheumatoid Arthritis (RA), juvenile arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, Ulcerative Colitis (UC), and Crohn's disease.

arket Dynamics

The tumor necrosis factor inhibitor drugs market growth is driven by rising incidences of various inflammatory conditions such as Rheumatoid Arthritis (RA), psoriasis, ankylosing spondylitis, Ulcerative Colitis (UC), Crohn's disease, and others.

The increasing prevalence of inflammatory conditions will drive market growth.

The tumor necrosis factor inhibitor drugs market growth is driven by rising incidences of various inflammatory conditions such as Rheumatoid Arthritis (RA), psoriasis, ankylosing spondylitis, Ulcerative Colitis (UC), Crohn's disease, and others. For instance, according to NIH, one of the major changes that occur during aging is the dysregulation of the immune response, leading to a chronic systemic inflammatory state. Therefore, the growing geriatric population is fueling the global market; for instance, Department of Economics and Social Affairs United States data shows that in 2020 the number of people aged 65 and over was around 272 million, which is predicted to reach 1.5 billion by 2050. Furthermore, according to the World Psoriasis Day consortium, around 125 million people worldwide, or 2 to 3 percent of the total population, have psoriasis; as per the University of Washington Medicine, 8% of the total healthy white Americans and 2-3% percent of the total healthy African Americans accounting for 300,000 Americans suffer ankylosing spondylitis. According to the Global RA Network, over 350 million people will have arthritis globally in 2021. In addition, according to NIH, in 2035, as compared to 2020, we expected a 2.5-fold rise in prevalence for Iran with 69 thousand cases, a 2.3-fold increment for North Africa and the Middle East with 220 thousand cases, quadrupling of the prevalence for India with 2.2 million cases, a 1.5-fold increase for East Asia region with 4.5 million cases, and a 1.6-fold elevation in prevalence for high‐income Asia‐Pacific and Southeast Asia regions with 183 and 199 thousand cases respectively.

Moreover, the research conducted by Crohn's & Colitis UK in 2022 indicates that 1 in every 123 people in the UK has either Crohn's disease or ulcerative colitis. Also, amounts to a total of nearly half a million people in the UK living with IBD. In addition, an increasing number of biosimilars entering the market is likely to increase the affordability and drive the consumption of TNF inhibitors, which in turn is projected to fuel the market globally during the forecast period.

The high cost of tumor necrosis factor inhibitor drugs, stringent regulatory framework, and high-quality standards will restrain the growth of the global tumor necrosis factor inhibitor drug market.

However, the high cost of tumor necrosis factor inhibitors drugs, stringent regulatory framework, and high-quality standards set by market leaders are some of the major factors hindering the market growth. For instance, according to NHS England, an interim reference price for the 40mg strength adalimumab is £3,550.00 per patient a year (pro rata), including homecare costs. In addition, as regulatory processes become stricter and more competitive, new products must have a major clinical benefit in terms of safety and efficacy or end-result over existing products, which leads to numerous head-to-head experiments between important market products, like Humira and Remicade, and new products or applicants for late-stage pipelines.

Industry analysis

The global tumor necrosis factor inhibitor drugs market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing, epidemiological, and pipeline analysis.

Segment Analysis

The Adalimumab (Humira) is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Adalimumab (Humira) held the largest market share in 2021 and is estimated to continue dominating the market throughout the forecast period (2022-2029). Owing to a large number of interventional clinical studies with Adalimumab. For instance, according to clinicaltrials.gov around 15 studies are active such as a comparative study between ABP 501 and Humira® in participants with moderate to severe plaque psoriasis sponsered by Amgen and estimated to be completed by January 10, 2023, a study for changing the course of crohn's disease by an early use of Adalimumab (CURE) sponsered by Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives and will be finished by March 2025, another long-term safety and efficacy study of Adalimumab in pediatric subjects with ulcerative colitis sponsered by AbbVie, predicted to compete on May 14, 2025, a study sponsered by Sinocelltech Ltd., with the pourpose to compare the efficacy and safety of SCT630 and Adalimumab (HUMIRA®) in adults with plaque psoriasis and assumed to be finshed by December 31, 2022, and a phase 3 randomized, open label multicenter trial to investigate the efficacy of a treat-to-target (T2T) treatment strategy with Secukinumab (AIN457) as a first-line biologic compared to a standard-of-care (SOC) treatment over 36 weeks in patients with active axial spondyloarthritis (axSpA) sponsered by Novartis Pharmaceuticals.

Geographical Analysis

The North American region holds the largest market share of the global tumor necrosis factor inhibitor drugs market

North America commanded the global tumor necrosis factor inhibitor drugs market in 2021 and is estimated to hold the largest market size over the forecast period (2022-2029) owing to the rising incidence of inflammatory disorders such as rheumatoid arthritis (RA), psoriasis, ankylosing spondylitis, ulcerative colitis (UC), Crohn's disease, and others. The United States and Canada have the highest incidence and prevalence of inflammatory bowel disease (IBD) in North America. According to the Centers for Disease Control and Prevention, in 2020, 1 in 4 adults had arthritis in the United States, and by 2040, over 78 million U.S. adults will have arthritis; according to the National Psoriasis Foundation studies, more than 8 million people in the U.S. had psoriasis in 2020. Hence, the demand for TNF drugs is highest in this region. Also, the presence of key manufacturers, proactive government initiatives, favorable reimbursement policies, and a large patient pool are driving the market in North America.

Competitive Landscape

Some of the major players in the tumor necrosis factor inhibitor drugs market are Amgen Inc, AbbVie Inc, Pfizer, Inc, Samsung Bioepis Co., Ltd., Sanofi, Novartis International AG, Johnson & Johnson Services, Merck & co., and others. The company has a vast portfolio in different regions. The key players are adopting various key strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the Tumor Necrosis Factor Inhibitor Drugs market globally. For instance, on July 27, 2021, AbbVie and Calico extended a collaboration focused on aging and age-related diseases. Also, in April 2021, Pfizer acquired Amplyx Pharmaceutical.

AbbVie Inc.

Overview:

AbbVie is a leading American publicly biopharmaceutical company and was founded in 2013 as a spin-off from Abbott Laboratories. AbbVie is headquartered in Illinois, United States. AbbVie achieved global sales of the drug at $5 billion in 2020. Has a global presence in 170+ countries.

Product Portfolio:

AbbVie Inc’s product portfolio contains HUMIRA® (Adalimumab).

The global Tumor Necrosis Factor Inhibitor Drugs market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.